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R  current  appreciation  of  the  involvement  of 
hrombospondin  1  (TSP1) 1 in  diverse  biological 
processes (Fig. 1; 1, 3, 25) extends far beyond the 
role initially attributed to the protein in platelet aggrega- 
tion and coagulation. This diversity of function has led to 
considerable  confusion  in  the  literature  and  skepticism 
among scientists  that  a  single  protein  can  subserve such 
protean, sometimes conflicting, functions. In this Commen- 
tary I will attempt to show that the ability of matricellular 
proteins, as defined below, to interact with a wide range of 
both matrix proteins and cell surface receptors can explain 
the complex biological functions of TSP1 and resolve many 
of the controversies regarding its mode of action. A conclu- 
sion of this analysis is that, even if allowances are made for 
some errors in experimentation and interpretation, the ma- 
jority of the reported functions of TSP1, divergent as they 
appear to be, are likely to be correct. 
The term "matricellular" is used in this analysis to refer 
to a group of modular, extracellular proteins whose func- 
tions are achieved by binding to matrix proteins as well as 
to cell surface receptors, or to other molecules such as cy- 
tokines and proteases that interact,  in turn, with the cell 
surface. In addition to TSP1, this group is likely to include 
members of the tenascin protein family, SPARC/osteonec- 
tin and its relatives, and osteopontin. Although matricellu- 
lar  proteins  can  be  associated  with  structural  elements 
such as collagen fibrils or basement membranes, it is pre- 
sumed that they do not contribute to the structural integ- 
rity of these elements. An association could, nevertheless, 
serve to  sequester  matricellular  proteins,  and  provide  a 
source of the proteins for subsequent  recruitment to the 
cell  surface.  It should  be  noted  that  the  distinction  be- 
tween  structural  matrix and matricellular proteins is not 
complete, since proteins such as fibronectin and laminin, 
which  do serve as integral components of structural  ele- 
ments,  also  have  adhesive  functions  and  play biological 
roles that partially overlap those of matricellular proteins. 
Furthermore, matricellular proteins may participate in the 
formation  of  structural  complexes  under  some  circum- 
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1. Abbreviation used in this paper: TSP1, thrombospondin 1. 
stances, for example, the postulated role of osteopontin in 
the mineralization of bone matrix. 
The Putative, Diverse Functions of TSP1 Cannot 
Be Explained by the Existence of Related TSPs, or 
Different Forms of TSP1 
As information regarding TSP1 has accumulated, the large 
and bewildering number of important biological processes 
in which the protein has been implicated has become ap- 
parent (Fig. 1). Moreover, in some cases, contradictory ef- 
fects have been ascribed to TSP1. Thus, experimental evi- 
dence  indicates  that  TSP1  can  be  both  adhesive  and 
antiadhesive, can foster and retard metastatic spread, can 
stimulate  and inhibit  angiogenesis,  and can increase  and 
reduce  proteolytic  activity and  fibrinolysis.  Could  all  of 
these experimental results be valid, or might some effects 
be attributed to different TSPs or to different isoforms of 
TSPI? The TSP family currently consists of five members, 
TSP1-4 and TSP5/COMP (cartilage oligomeric matrix pro- 
tein). Homotrimeric TSP1 and TSP2 are structurally simi- 
lar but differ from pentameric TSP3, 4 and 5 (1-3). TSP1 
and 2 are expressed widely in tissues of the developing and 
adult mouse at both the mRNA and protein levels (6, 14, 
15), whereas the distribution of TSP3-5 mRNAs is thought 
to be more limited. This difference in tissue distribution, 
together with structural differences, indicates that the two 
MOLECULAR  CELLULAR  BIOLOGICAL 
FUNCTION  IS'UNCTION  PROCI~8 
~YONIC 
DIIVELOPM  BNT 
TIIMIUIg 
DII~ImlN'rlATION 
BINDING !"0  CILL iqlOILII"ImAYION 
CILL4UII~ACl  NIURnX OUTGItOV~I'W 
IWCKPTORS  ADmmlOPIICI~I~  8HAPg  AXONAL  GUIDANCK/ 
NIgRVIg  IIgGKNERATION 
BINDING OI  e CY'FOIKINIg~  cl~[ID~o~r~o{1~ 
pl(Yl'l~AlJl~!  HAFI'O'rAXIS/  TUklOII OROWYH AND 
M1GI~'JI'ION  HFrAfrABIS 
|XTRACELLULAR 
PIOTIIN INTEIACTIONa  PHAGOCYTO61S  ANGIOGKNIIM 
JI~I'ON81 TO IN.JUIy 
INFLAMIdATION 
COAGULATION/ 
FIBRINOLYSI8 
Figure 1.  The  diverse  roles  of TSP1.  Biological  processes  in 
which TSP1 is implicated  are listed  in the right panel, cellular 
functions  deduced from experiments in vitro are in the center 
panel,  and molecular interactions  determined with  the purified 
protein are on the left. 
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Although the extent to which the functions of TSP1 and 
TSP2 are related or overlapping is uncertain, a distinction 
between the  two proteins is suggested by their different 
tissue distribution  (14, 15), by the observation that TSP1, 
but not TSP2, is transiently induced during osteogenic dif- 
ferentiation  of MC3T3-E1  cells  (28),  and by the finding 
that the promoter sequences of the mouse TSP1 and TSP2 
genes  are  different  (2).  The  latter finding  is  compatible 
with the demonstration that the TSP1  gene is highly re- 
sponsive to growth factors, whereas the TSP2 gene is not 
(2). A  direct demonstration of a functional difference be- 
tween TSP1 and TSP2 was recently reported by Pellerin et 
al. (22), who found that TSP2 inhibited the spreading of 
bovine adrenocortical cells, whereas TSP1 did not. South- 
ern  blot  analysis  and  in  situ  chromosomal  localization 
studies are consistent with a single genetic locus for TSP1 
in mice and humans. Nevertheless, isoforms could result 
from alternate  splicing,  as  has  been  documented  for fi- 
bronectin, tenascin, and many other extracellular proteins. 
Typically, Northern blot analyses reveal only a single 6-kb 
band for TSP1, but alternate splice forms might be gener- 
ated in a cell- or tissue-specific manner and thus might be 
difficult to detect. To date, only one report of unpublished 
data  supports  the  existence  of  a  low  molecular  weight 
form of TSP1, which could be the result of alternate splic- 
ing (10). Therefore, the process, if it exists, is probably not 
common. A  second candidate for an alternate splice form 
of TSP1,  the 140-kD fragment of hamster TSP1  that has 
been  shown  to  function  as  an  inhibitor  of angiogenesis 
(11), is more likely to result from limited proteolysis of the 
intact protein. 
Heterogeneity in TSP1 could also be introduced by the 
formation of heterotrimers between TSP1 and TSP2. A re- 
cent  study  presented  evidence  for heterotrimeric  TSP1/ 
TSP2 molecules, based on their isolation by type-specific 
antibodies (21). The validity of these results depends criti- 
cally on  the  ability  to  exclude  association  of TSP1  and 
TSP2 homotrimeric molecules prior to immunoprecipita- 
tion. Since association of TSPs may be highly dependent 
on the presence of other proteins, ionic strength, and other 
factors, suitable control experiments could be difficult to 
design. The experiments of O'Rourke et al. (21) will there- 
fore require confirmation. Some indication that heterotri- 
meric  TSP1/TSP2  molecules,  if  present,  might  not  be 
common is provided by the findings that mRNAs for TSP1 
and TSP2  are separated spatially and temporally during 
mouse  development  (14),  and  that  immunofluorescence 
studies  show  distinctly  different  patterns  for  TSP1  and 
TSP2 in cultures  of differentiating embryonal carcinoma 
cells (16). Thus, although some early studies of the immu- 
nolocalization  of TSP1,  which  were performed before it 
was known that related TSPs existed, might have confused 
the different TSPs, it seems unlikely that any of the prop- 
erties of TSP1 listed in Fig. 1 can be ascribed exclusively to 
another TSP family member, or to a different isoform of 
TSP1. It remains a possibility that some contradictory ef- 
fects of TSP1 can be explained by experimental variables. 
For example, the activity of soluble TSP1 could differ from 
that of TSP1 bound to a substratum. 
The Participation of TSPI in Diverse and Complex 
Biological Processes Can Be Explained by an Extensive 
Repertoire of Molecular and Cellular Interactions 
If it is the case that the complex functions of TSP1 cannot 
be  attributed  to  different  family members  or  isoforms, 
how can they be achieved? TSP1 binds and activates latent 
TGF~I, and serves as  a  competitive inhibitor  of several 
serine proteases (Fig. 2; 12, 27). Since the conformation of 
the CaE+-binding repeats in TSP1, and thus the affinity for 
binding to integrins  and proteases, can be influenced  by 
Ca  2÷  concentration  (12,  29),  the  ionic milieu of the  cell 
could  also  regulate  TSP1  function.  The  interaction  of 
TSP1  with  proteins  that  form  structural  elements  (col- 
lagens, proteoglycans, fibronectin,  laminins)  might serve 
to present TSP1 to the cell surface, and might also modu- 
late the interaction of those proteins with their own recep- 
tors. The effects of these interactions  are likely to influ- 
ence cell proliferation, adhesion, and migration in different 
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Figure 2.  Location of ligand- 
binding  sites for cell surface 
receptors (top) and protein- 
protein  interactions  (bot- 
tom)  within  the  domain 
structure of TSP1. The struc- 
tural plan of TSP1 consists of 
an  NH2-terminal  domain,  a 
type I procollagen  homology 
region  (PC), three  type  I 
(TSP  or properdin)  repeats, 
three type II (EGF-like) re- 
peats, seven type III (Ca  2÷- 
binding)  repeats,  and  a 
COOH-terminal domain.  In 
several instances (52- and 60- 
kD receptors, TGF-[31, pro- 
teases), specific peptide sequences within these domains have been implicated in these interactions.  The last type III repeat contains an 
RGD sequence but the assignment of all integrin-binding  sites to the type III repeats has not been established. A single chain in the ho- 
motrimeric protein is shown. The numbers indicate  amino acids, with 1 representing the initiating  methionine in the signal peptide. 
HSPG and CSPG:  heparan and chondroitin  sulfate proteoglycans,  respectively. 
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trix context. 
TSP1 also binds to a disconcertingly large number of cell 
surface  molecules  that  include  proteoglycans,  integrins 
and non-integrin receptors (Fig.  2).  The signaling  path- 
ways that are affected, and the intracellular metabolic con- 
sequences of such interactions, are essentially unknown. It 
is likely that different cells in different locations will ex- 
press  a  distinct  repertoire of receptors. Furthermore, it 
seems possible that some biological effects require the en- 
gagement of more than one receptor by a single TSP1 mol- 
ecule. Thus, the presence at the cell surface of a molecule 
that binds to only a subset of these receptors could modu- 
late the functional consequences of TSP1 action. Viewed 
in this light, the participation of TSP1 in the diverse bio- 
logical processes listed in Fig. 1, and its conflicting effects, 
are not surprising and are a direct consequence of the mul- 
tiple interactions summarized in Fig. 2. 
What Role Does TSP1 Play in Cell Proliferation? 
The gene that encodes TSP1 is rapidly induced by PDGF, 
serum, and other growth factors (17); nevertheless, a role 
for a matricellular protein in the regulation of cell growth 
seems  surprising. There is  little doubt that TSP1, either 
alone or in concert with PDGF or EGF, can stimulate pro- 
liferation of smooth muscle cells, mesangial cells, and fi- 
broblasts (3, 18, 20). This effect could result from the bind- 
ing and presentation of growth factors to their receptors, 
but such interactions remain to be demonstrated. In con- 
trast, TSP1 either has no direct effect or inhibits endothe- 
lial cell growth (20, 30, 32). Since TSP1 binds and activates 
latent TGFI31, cell-specific effects might reflect a differen- 
tial response to this multifunctional growth factor. Equally 
relevant are recent findings which show that, in mesangial 
cells, TSP1 stimulates the secretion of PDGF and EGF (18). 
The existence of such a positive feedback loop could explain 
the interdependence of cellular responses such as prolifer- 
ation, chemotaxis, and migration on TSP1 and growth fac- 
tors. The lack of response of most endothelial cells to PDGF 
could also account for the failure of TSP1 to stimulate en- 
dothelial cell growth. Finally, the differential effects of mod- 
ification of protease activity, and the display of different 
subsets of receptors, could contribute to cell-specific effects 
of TSP1. 
What Role Does TSP1 Play in the Neoplastic Process 
and in Angiogenesis? 
Neoplasia,  comprising  neoplastic  conversion,  malignant 
progression,  tumor  growth,  and  metastasis,  is  a  highly 
complex process that is species, cell, and tissue dependent. 
Given its mode of action at the cell surface, it seems un- 
likely that TSP1 plays a direct role in the initial steps in 
this process. It is also unnecessary to postulate, a priori, 
that effects of TSP1 will be found to be concordant in the 
two latter  steps,  i.e.,  tumor growth  and  metastasis.  The 
case for a positive role for TSP1 in metastatic potential can 
be made as follows. TSP1 serves as an adhesion factor for 
many neoplastic cells and stimulates chemotaxis and hap- 
totaxis. In the presence of TSP1, microemboli consisting of 
tumor cells and platelets are more likely to attach to en- 
dothelial cells and, aided by the ability of TSP1 to foster 
conversion of plasminogen to plasmin, traverse capillary 
and lymphatic endothelia (31). To the extent that TSP1 
can also stimulate proliferation of such tumor cells, growth 
of metastatic foci would be fostered. The demonstration of 
serum-  and  anchorage-independent growth  in  clones  of 
NIH 3T3 cells expressing high levels of TSP1, and neutral- 
ization of the effect by monoclonal antibodies to TSP1 (4), 
and the reversal of the malignant phenotype of squamous 
carcinoma cells by antisense RNA-mediated reduction in 
TSP1 (5), favor such a model. On the other hand, a nega- 
tive correlation between metastatic potential and expres- 
sion of TSP1 was recently found in several tumor cell lines 
(34), and expression of a TSP1 cDNA in human breast car- 
cinoma  cells  reduced  tumor  growth  and  metastases  in 
nude mice (33). A  resolution of these apparently conflict- 
ing conclusions can be found in differences in the nature 
and number of TSP1 receptors characteristic of the vari- 
ous tumor cell lines, in their ability to activate and respond 
to TGFI3 or proteases, and/or to initiate a positive regula- 
tory loop in which endogenous growth factors are secreted 
in response to TSP1. 
Regulation of neovascularization as a factor in control 
of tumor growth has received considerable attention (9). 
An inhibitory role for TSP1 was demonstrated in the an- 
giogenic response to basic FGF and to conditioned me- 
dium from psoriatic keratinocytes, as determined by the 
rodent corneal assay (11, 19, 30), and in the formation of 
cords and tubes by endothelial cells in vitro (13). The find- 
ing that p53,  a  prominent tumor suppressor gene, posi- 
tively regulates TSP1 expression (7) provides supportive 
evidence for such a role. In contrast, the addition of TSP1 
to aortic explants, embedded in a  collagen or fibrin gel, 
stimulated microvessel formation (20). This effect was at- 
tributed not to stimulation of endothelial proliferation but 
to growth of myofibroblasts, which presumably produce 
angiogenic factors. A  major consequence of activation of 
TGF-13  by TSP1  is  stimulation  of PAI-1  production by 
many cells (26). PAI-1 could affect at least two steps that 
are  important  in  angiogenesis:  disruption  of  basement 
membranes and cell-matrix interactions. Thus, regulation 
of tumor growth by TSP1 reflects the complex interplay of 
positive and negative influences of the protein on neoplas- 
tic  cells  and  on  associated  stromal  and  vascular  cells. 
These effects, in turn, can be attributed to the various in- 
teractions of TSP1 with cells in the neoplasm,  and with 
stromal elements which could serve either to present TSP1 
to cells or to sequester it from them (Fig. 2). 
Perspectives 
Given its multiple interactions, the pleotropic, sometimes 
conflicting, functions of TSP1 can be seen as an inherent 
consequence of its structure.  As  a  matricellular protein, 
TSP1 functions as an integrator of the complex informa- 
tion imparted by extracellular protein motifs and cell sur- 
face receptors. The specificity of its function would seem 
to be dictated by the combinatorial arrangement of avail- 
able  cell-surface and  extracellular ligands.  In effect, the 
complexity of the pericellular environment provides an ex- 
planation for the diverse functions of TSP1. 
If, indeed, TSP1 participates in the many complex func- 
tions described in Fig. 1, one would expect that an animal 
Bornstein Thrombospondin 1, A Matricellular Protein  505 lacking the protein would not be viable.  Nevertheless,  a 
preliminary report indicates that mice with a targeted dis- 
ruption of the TSP1  gene  display  at most  a  very subtle 
phenotype (Polverini, P. J., L.  A.  DiPietro,  V. M. Dixit, 
R.O.  Hynes,  and  J.  Lawler.  1995.  Thrombospondin  1 
knockout mice show delayed organization and prolonged 
neovascularization of skin wounds. FASEB (Fed. Am. Soc. 
Exp. BioL) J. 9:272a.), and mice lacking tenascin C are ap- 
parently normal (24). How can one explain such a para- 
dox? Even though some proteins may be produced in loca- 
tions  where  they  have  no  function  because  it  is  more 
economical for an organism to waste superfluous protein 
than it is to regulate expression tightly (8), I do not believe 
that this phenomenon provides the complete answer. Nor 
do I believe that many of the functions ascribed to TSP1 
and tenascin C are based on artifacts of experimentation 
in vitro. It seems  likely that one or more  defects  will be 
found in these "null" mice when they can be subjected to 
the correct critical tests. Furthermore, the sudden loss of 
TSP1 in a postnatal animal could have very different, and 
more serious, consequences.  The functions described  for 
TSP1  in this Commentary are almost all in the nature of 
regulatory  or  modulating  effects.  Compensatory  adjust- 
ments for lack of TSP1 might therefore be made in an ani- 
mal deprived of the protein on a genetic basis, a process 
that could be termed "genetic adaptation". A  related phe- 
nomenon is the known ability of genetic modifiers, present 
in different murine genetic backgrounds, to affect the pen- 
etrance of mutant phenotypes differentially. If these con- 
siderations  have  validity,  targeted  disruption  of  other 
matricellular protein genes may also prove, on initial assess- 
ment, to have relatively innocuous consequences. 
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